Lyell Immunopharma, Inc. (LYEL): Price and Financial Metrics
GET POWR RATINGS... FREE!
LYEL POWR Grades
- Growth is the dimension where LYEL ranks best; there it ranks ahead of 78.91% of US stocks.
- The strongest trend for LYEL is in Value, which has been heading up over the past 177 days.
- LYEL's current lowest rank is in the Momentum metric (where it is better than 4.75% of US stocks).
LYEL Stock Summary
- LYEL's went public 1.78 years ago, making it older than only 4.98% of listed US stocks we're tracking.
- As for revenue growth, note that LYEL's revenue has grown 695.15% over the past 12 months; that beats the revenue growth of 98.74% of US companies in our set.
- In terms of volatility of its share price, LYEL is more volatile than 90.85% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to LYELL IMMUNOPHARMA INC, a group of peers worth examining would be MVIS, INMB, RGTI, LOOP, and ORMP.
- LYEL's SEC filings can be seen here. And to visit LYELL IMMUNOPHARMA INC's official web site, go to www.lyell.com.
LYEL Valuation Summary
- In comparison to the median Healthcare stock, LYEL's price/earnings ratio is 111.64% lower, now standing at -2.7.
- LYEL's price/sales ratio has moved down 522.9 over the prior 22 months.
Below are key valuation metrics over time for LYEL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LYEL | 2023-03-24 | 5.9 | 0.6 | -2.7 | -2.4 |
| LYEL | 2023-03-23 | 6.0 | 0.6 | -2.8 | -2.4 |
| LYEL | 2023-03-22 | 6.1 | 0.6 | -2.8 | -2.5 |
| LYEL | 2023-03-21 | 6.5 | 0.7 | -3.0 | -2.7 |
| LYEL | 2023-03-20 | 6.4 | 0.7 | -3.0 | -2.6 |
| LYEL | 2023-03-17 | 6.3 | 0.6 | -2.9 | -2.6 |
LYEL Price Target
For more insight on analysts targets of LYEL, see our LYEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $25.50 | Average Broker Recommendation | 1.38 (Strong Buy) |
LYEL Stock Price Chart Interactive Chart >
LYEL Price/Volume Stats
| Current price | $2.15 | 52-week high | $8.74 |
| Prev. close | $2.34 | 52-week low | $1.83 |
| Day low | $2.13 | Volume | 795,100 |
| Day high | $2.36 | Avg. volume | 1,014,234 |
| 50-day MA | $2.55 | Dividend yield | N/A |
| 200-day MA | $4.90 | Market Cap | 536.66M |
Lyell Immunopharma, Inc. (LYEL) Company Bio
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers, as well as ovarian and other solid tumors; LYL845, an IV administered autologous TIL therapy for multiple solid tumors; and NY-ESO-1, a T cell product candidate for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.
Latest LYEL News From Around the Web
Below are the latest news stories about LYELL IMMUNOPHARMA INC that investors may wish to consider to help them evaluate LYEL as an investment opportunity.
Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains?Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 47% stakeKey Insights Given the large stake in the stock by institutions, Lyell Immunopharma's stock price might be vulnerable... |
Lyell Immunopharma (LYEL) Reports Q4 Loss, Tops Revenue EstimatesLyell Immunopharma (LYEL) delivered earnings and revenue surprises of 90.32% and 1,597.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022Cash, cash equivalents and marketable securities of $710.3 million as of December 31, 2022 supports advancing robust pipeline into 2026, through multiple clinical milestonesPhase 1 clinical trials initiated for two wholly-owned product candidates for the treatment of solid tumorsNonclinical data highlighting CAR T cell and TIL product candidates designed for differentiated potency and durability presented at multiple scientific conferences SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWI |
Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com... |
LYEL Price Returns
| 1-mo | -10.42% |
| 3-mo | -38.04% |
| 6-mo | -70.67% |
| 1-year | -57.43% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -38.04% |
| 2022 | -55.17% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...